Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia

por Oram, S H, Thoms, J, Sive, J I, Calero-Nieto, F J, Kinston, S J, Schütte, J, Knezevic, K, Lock, R B, Pimanda, J E, Göttgens, B
Publicado 2013

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response

por Thoms, J W, Dal Pra, A, Anborgh, P H, Christensen, E, Fleshner, N, Menard, C, Chadwick, K, Milosevic, M, Catton, C, Pintilie, M, Chambers, A F, Bristow, R G
Publicado 2012

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy

por Boström, P.J., Thoms, J., Sykes, J., Ahmed, O., Evans, A., van Rhijn, B.W. G., Mirtti, T., Stakhovskyi, O., Laato, M., Margel, D., Pintilie, M., Kuk, C., Milosevic, M., Zlotta, A.R., Bristow, R.G.
Publicado 2016